Study guide
3.2 Rapid Sequence Induction (RSI) - Pretreatment & Induction Agents
IBSC CCP-C Certified Critical Care Paramedic Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Strategy
1.1 About the CCP-C Exam 1.2 CCP-C Study Strategy & Exam Tactics
2 Chapter 2: Transport and Safety (Part 1)
2.1 Crew Resource Management & Sterile Cockpit Rule 2.2 Transport Risk Assessment & Mission Decision-Making 2.3 Aircraft and Ground Transport Safety Protocols
3 Chapter 2: Transport and Safety (Part 2)
2.4 Environmental Transport Stressors & Gas Laws 2.5 Transport Equipment Management & Post-Mission Operations
4 Chapter 3: Airway, Anesthesia, and Analgesics (Part 1)
3.1 Advanced Airway Assessment & Difficult Airway Identification 3.2 Rapid Sequence Induction (RSI) - Pretreatment & Induction Agents 3.3 Neuromuscular Blockade - Depolarizing vs Non-Depolarizing Agents 3.4 Post-Intubation Sedation, Analgesia & Dissociative Maintenance 3.5 Transport Ventilator Setup & Primary Ventilation Modes
5 Chapter 3: Airway, Anesthesia, and Analgesics (Part 2)
3.6 Mechanical Ventilator Waveforms, Loops & Oxygenation Titration 3.7 Ventilator Alarm Troubleshooting & Peak vs Plateau Pressures 3.8 Rescue Airway Devices, Video Laryngoscopy & Surgical Cricothyrotomy 3.9 Neuromuscular Reversal & Vasoactive Airway Support 3.10 Transport Airway Management in Unique Environments & Extubation
6 Chapter 4: General Medical Patient
4.1 Sepsis, Severe Sepsis & Septic Shock Resuscitation 4.2 Endocrine Emergencies (DKA, HHS, Adrenal Crisis, Thyroid Storm) 4.3 Renal and Hepatic Emergencies in Transport
7 Chapter 5: Cardiac Patient
5.1 Acute Coronary Syndromes & Infarct Specific Complications 5.2 Invasive Hemodynamic Monitoring 5.3 Vasoactive & Inotropic Medication Titration 5.4 Mechanical Circulatory Support & Post-Cardiac Arrest Care
8 Chapter 6: Neurological Patient
6.1 Traumatic Brain Injury & Intracranial Pressure (ICP) Management 6.2 Acute Ischemic Stroke, Hemorrhagic Stroke & Subarachnoid Hemorrhage 6.3 Status Epilepticus, Spinal Cord Injury & Neurogenic Shock
9 Chapter 7: Respiratory Patient
7.1 Acute Respiratory Distress Syndrome (ARDS) & Lung-Protective Ventilation 7.2 Severe Asthma & COPD Exacerbations in Critical Care 7.3 Chest Tube Management, Pleural Drains & Tension Pneumothorax 7.4 Pulmonary Embolism, Pulmonary Hypertension & Transport Respiratory Meds
10 Chapter 8: Toxic Exposure and Environmental Patient
8.1 Toxicology Emergencies, Toxidromes & Antidote Therapy 8.2 Environmental Emergencies (Hypothermia, Hyperthermia, Frostbite) 8.3 Submersion, Diving Emergencies & Envenomation/HazMat
11 Chapter 9: Trauma and Burn Patient
9.1 Hemorrhagic Shock Resuscitation & Massive Transfusion Protocols (MTP) 9.2 Severe Thoracic & Abdominal Trauma Management 9.3 Thermal, Chemical & Electrical Burn Assessment & Fluid Resuscitation 9.4 Musculoskeletal Trauma, Pelvic Fractures & Compartment Syndrome
12 Chapter 10: Maternal and Fetal Medicine
10.1 High-Risk Obstetric Assessment & Hypertensive Disorders of Pregnancy 10.2 Obstetric Hemorrhage, Placental Abruption & Preterm Labor 10.3 Emergency Transport Delivery, Umbilical Cord Prolapse & Fetal Monitoring
13 Chapter 11: Pediatric Patient
11.1 Pediatric Critical Care Airway & Transport Ventilation 11.2 Pediatric Shock, Dehydration & Weight-Based Dosing 11.3 Neonatal Resuscitation Program (NRP) & Transport of the Critical Neonate
14 Chapter 12: Special Populations
12.1 Bariatric Critical Care Transport & Positional Management 12.2 Geriatric Critical Care & Patients with Specialized Medical Technology
15 Chapter 13: Professional Considerations
13.1 Legal Aspects, EMTALA & Transport Ethics 13.2 Quality Improvement, Transport Safety Research & Evidence-Based Practice
3.2 Rapid Sequence Induction (RSI) - Pretreatment & Induction Agents
Key Takeaways Explain This Topic AI
Rapid Sequence Induction (RSI) follows the structured 7 Ps operational sequence: Preparation, Preoxygenation, Pretreatment, Paralysis with Induction, Protection & Positioning, Placement with Proof, and Post-intubation management.
Etomidate (0.3 mg/kg IV) provides hemodynamically neutral induction, making it ideal for trauma and shock, but causes transient 11-beta-hydroxylase adrenal suppression.
Ketamine (1.5–2.0 mg/kg IV) stimulates catecholamine release to preserve blood pressure and acts as a direct bronchodilator, making it the preferred induction agent for status asthmaticus and septic shock.
Propofol (1.5–2.5 mg/kg IV) causes profound venodilation and arterial vasodilation leading to severe hypotension, and is contraindicated in hemodynamically unstable or shocked patients.
Pretreatment agents (Fentanyl, Lidocaine, Atropine) are administered 3 minutes prior to induction to blunt reflex sympathetic surges, increased intracranial pressure (ICP), or bradycardia.
Last updated: July 2026
Rapid Sequence Induction (RSI) — Pretreatment & Induction Agents
Rapid Sequence Induction (RSI) is the administration of a potent induction agent followed immediately by a rapid-acting neuromuscular blocking agent to induce unconsciousness and flaccid paralysis. This technique facilitates emergency endotracheal intubation while minimizing the risk of gastric aspiration in unfasted critical care patients. In transport medicine, selecting the correct pharmacological regimen requires balancing neurological goals against hemodynamic stability.
1. The 7 Ps of Rapid Sequence Induction
RSI follows a rigorous, chronological execution model known as the 7 Ps :
Preparation ( T − 10 min T - 10\text{ min} T − 10 min ): Assemble all primary and rescue airway equipment, suction, monitoring, and vascular access. Conduct the SOAP ME operational checklist ( S uction, O xygen, A irway equipment, P harmacology, M onitors/ETCO2, E rythrocyte/Emergency plans).
Preoxygenation ( T − 5 min T - 5\text{ min} T − 5 min ): Replace nitrogen in the functional residual capacity (FRC) with 100% oxygen using a non-rebreather mask at 15+ L/min or non-invasive positive pressure ventilation (NIV/BiPAP) for 3 minutes, or 8 deep vital-capacity breaths. Apply passive apneic oxygenation via high-flow nasal cannula at 15 to 150 L/min ( NO DESAT protocol).
Pretreatment ( T − 3 min T - 3\text{ min} T − 3 min ): Administer adjunctive agents to mitigate the physiological complications of laryngoscopy (sympathetic surge, ICP spikes, bronchospasm, or bradycardia).
Paralysis with Induction ( T − 0 sec T - 0\text{ sec} T − 0 sec ): Administer the selected rapid-acting induction agent by rapid IV push, followed immediately by the neuromuscular blocking agent.
Protection & Positioning ( T + 30 sec T + 30\text{ sec} T + 30 sec ): Maintain passive apneic oxygenation. Position the patient in the ear-to-sternal notch alignment (ramped position for obese patients). Avoid routine BVM ventilation to prevent gastric distension unless severe desaturation occurs.
Placement with Proof ( T + 45 to 60 sec T + 45\text{ to } 60\text{ sec} T + 45 to 60 sec ): Perform direct or video laryngoscopy, pass the ETT through the vocal cords under direct visualization, inflate the cuff, and confirm placement using continuous quantitative waveform capnography ( E T C O 2 ETCO_2 ETC O 2 ) and bilateral auscultation.
Post-Intubation Management ( T + 2 min T + 2\text{ min} T + 2 min ): Secure the tube, establish mechanical ventilation, and initiate continuous IV sedation and analgesia infusions.
2. Pretreatment Pharmacology
Pretreatment agents are given 3 minutes prior to induction to blunt adverse physiological reflexes triggered by laryngoscopy:
Fentanyl
Dose: 3 mcg/kg IV 3\text{ mcg/kg IV} 3 mcg/kg IV slowly over 30 to 60 seconds.
Mechanism: Synthetic opioid agonist acting on μ \mu μ -receptors; blunts the sympathetic surge (hypertension and tachycardia) caused by laryngeal manipulation.
Indications: Suspected intracranial hemorrhage, Traumatic Brain Injury (TBI) with elevated ICP, acute aortic dissection, or severe coronary artery disease.
Contraindications & Pearls: Avoid as a monotherapy in decompensated shock or severe hypotension, as it reduces compensatory sympathetic tone.
Lidocaine
Dose: 1.5 mg/kg IV 1.5\text{ mg/kg IV} 1.5 mg/kg IV .
Mechanism: Class IB antiarrhythmic and local anesthetic; blunts airway cough reflexes, mitigates reflex bronchospasm, and attenuates spikes in ICP during airway manipulation.
Indications: Severe reactive airway disease (status asthmaticus, COPD exacerbation) and traumatic brain injury with signs of elevated ICP.
Atropine
Dose: 0.02 mg/kg IV 0.02\text{ mg/kg IV} 0.02 mg/kg IV (minimum dose 0.1 mg 0.1\text{ mg} 0.1 mg , maximum single dose 0.5 mg 0.5\text{ mg} 0.5 mg in pediatrics).
Mechanism: Competitive muscarinic acetylcholine receptor antagonist.
Indications: Prevention of reflex vagal bradycardia in pediatric patients ( < 1 year < 1\text{ year} < 1 year old) undergoing intubation, or pediatrics receiving succinylcholine (or adult repeated succinylcholine dosing).
3. Induction Agents Pharmacology
Induction agents produce rapid loss of consciousness. The choice of agent depends primarily on the patient’s hemodynamic status, neurological state, and respiratory pathology.
Etomidate (Amidate)
Class: Imidazole derivative / non-barbiturate hypnotic.
Induction Dose: 0.3 mg/kg IV 0.3\text{ mg/kg IV} 0.3 mg/kg IV (range 0.2 − 0.4 mg/kg 0.2 - 0.4\text{ mg/kg} 0.2 − 0.4 mg/kg ). Total dose usually 20–30 mg IV push.
Onset & Duration: Onset < 15 − 30 seconds < 15-30\text{ seconds} < 15 − 30 seconds ; Duration 5 − 10 minutes 5-10\text{ minutes} 5 − 10 minutes .
Hemodynamic Impact: Hemodynamically neutral. Preserves Systemic Vascular Resistance (SVR), Mean Arterial Pressure (MAP), and Cardiac Output (CO). Does not cause histamine release.
Neurological Impact: Decreases Cerebral Blood Flow (CBF), Cerebral Metabolic Rate of Oxygen consumption ( C M R O 2 CMRO_2 CMR O 2 ), and Intracranial Pressure (ICP) while preserving Cerebral Perfusion Pressure (CPP).
Key Adverse Effect: Transient inhibition of 11 β 11\beta 11 β -hydroxylase, suppressing adrenal steroidogenesis for 12 to 24 hours. While clinically controversial in sepsis, etomidate remains widely used for single-dose emergency induction in hemodynamically unstable patients.
Ketamine (Ketalar)
Class: Phencyclidine (PCP) derivative / Dissociative anesthetic.
Induction Dose: 1.5 − 2.0 mg/kg IV 1.5 - 2.0\text{ mg/kg IV} 1.5 − 2.0 mg/kg IV ( 4.0 − 5.0 mg/kg IM 4.0 - 5.0\text{ mg/kg IM} 4.0 − 5.0 mg/kg IM if vascular access absent).
Onset & Duration: Onset 30 − 60 seconds 30-60\text{ seconds} 30 − 60 seconds IV; Duration 10 − 20 minutes 10-20\text{ minutes} 10 − 20 minutes .
Hemodynamic Impact: Sympathomimetic. Inhibits central and peripheral catecholamine reuptake, causing increases in heart rate, blood pressure, SVR, and cardiac output. Highly advantageous in shock states.
Respiratory Impact: Direct smooth muscle relaxant causing potent bronchodilation . Preserves functional residual capacity and intercostal/diaphragmatic respiratory drive.
Indications: Severe status asthmaticus, septic shock, trauma with hemorrhagic shock, and undifferentiated hypotension.
Contraindications & Pearls: Relative contraindication in severe ischemic heart disease or active myocardial infarction, as increased myocardial oxygen demand can worsen ischemia. Historical concerns regarding elevated ICP have been disproven in ventilated, normocarbic head trauma patients.
Propofol (Diprivan)
Class: Alkylphenol derivative / sedative-hypnotic.
Induction Dose: 1.5 − 2.5 mg/kg IV 1.5 - 2.5\text{ mg/kg IV} 1.5 − 2.5 mg/kg IV (reduced to 0.5 − 1.0 mg/kg 0.5 - 1.0\text{ mg/kg} 0.5 − 1.0 mg/kg in elderly or hemodynamically fragile patients).
Onset & Duration: Onset 15 − 30 seconds 15-30\text{ seconds} 15 − 30 seconds ; Duration 5 − 10 minutes 5-10\text{ minutes} 5 − 10 minutes .
Hemodynamic Impact: Profound Vasodilator & Myocardial Depressant. Causes significant drops in SVR, preload, stroke volume, and MAP due to direct vascular smooth muscle relaxation and blunting of baroreceptor reflexes.
Neurological Impact: Potent cerebral protectant; markedly decreases C M R O 2 CMRO_2 CMR O 2 , CBF, and ICP. Anticonvulsant properties.
Indications: Status epilepticus, severe hypertensive head injury with normal perfusion, or hyperdynamic intubations.
Contraindications: Absolute contraindication in shock, severe hypotension ( S B P < 90 mmHg SBP < 90\text{ mmHg} SBP < 90 mmHg ), or hypovolemia.
Midazolam (Versed)
Class: Benzodiazepine.
Induction Dose: 0.2 − 0.3 mg/kg IV 0.2 - 0.3\text{ mg/kg IV} 0.2 − 0.3 mg/kg IV (Note: This is significantly higher than procedural sedation dosing of 0.05 mg/kg 0.05\text{ mg/kg} 0.05 mg/kg ). Total dose typically 10–20 mg IV push.
Onset & Duration: Onset 60 − 180 seconds 60-180\text{ seconds} 60 − 180 seconds (slowest onset of all induction agents); Duration 15 − 30 minutes 15-30\text{ minutes} 15 − 30 minutes .
Hemodynamic Impact: Moderate vasodilator and direct myocardial depressant; causes unpredictable hypotension when combined with opioids.
Clinical Status: Suboptimal primary induction agent for RSI due to delayed onset and high risk of cardiovascular collapse at full induction doses. Reserved for situations where etomidate, ketamine, and propofol are unavailable.
Induction Pharmacology Matrix
Induction Agent RSI Dose Onset Duration MAP / SVR Impact Bronchial Tone Primary Clinical Indications
Etomidate 0.3 mg/kg IV 0.3\text{ mg/kg IV} 0.3 mg/kg IV 15 − 30 s 15-30\text{ s} 15 − 30 s 5 − 10 min 5-10\text{ min} 5 − 10 min Neutral (Unchanged) Neutral Undifferentiated shock, trauma, cardiac compromise, sepsis
Ketamine 1.5 − 2.0 mg/kg IV 1.5-2.0\text{ mg/kg IV} 1.5 − 2.0 mg/kg IV 30 − 60 s 30-60\text{ s} 30 − 60 s 10 − 20 min 10-20\text{ min} 10 − 20 min Increased (Sympathomimetic) Potent Bronchodilation Status asthmaticus, septic shock, hemorrhagic shock
Propofol 1.5 − 2.5 mg/kg IV 1.5-2.5\text{ mg/kg IV} 1.5 − 2.5 mg/kg IV 15 − 30 s 15-30\text{ s} 15 − 30 s 5 − 10 min 5-10\text{ min} 5 − 10 min Decreased (Profound Drop) Moderate Bronchodilation Status epilepticus, severe hypertensive head trauma
Midazolam 0.2 − 0.3 mg/kg IV 0.2-0.3\text{ mg/kg IV} 0.2 − 0.3 mg/kg IV 60 − 180 s 60-180\text{ s} 60 − 180 s 15 − 30 min 15-30\text{ min} 15 − 30 min Decreased (Variable Drop) Neutral Backup agent when preferred hypnotics unavailable